This is a couple days old


cardiac device maker Abiomed (ABMD) beat quarterly estimates and guided the current fiscal year above consensus Tuesday, but its elevated stock still slipped in trading.

For its fiscal Q4 ended March 31, Abiomed’s sales totaled $94 million, up 39% from the year-earlier quarter and beating analysts’ consensus by about $3 million, according to Thomson Reuters. Earnings fell 14% to 24 cents a share but still beat consensus by 9 cents.

The earnings decline in both Q3 and Q4 were due to tough year-over-year comparisons, but analysts expect growth to return in the current quarter and accelerate thereafter. Abiomed supported this with its guidance for the current fiscal year: $430 million to $445 million in sales vs. last year’s $329.5 million, beating consensus of $421 million. It does not provide EPS guidance but said operating margin should be 18% to 20%, which would be flat to slightly below last year’s.

The margin guidance might have been a bit below expectations.


Antalffy still was positive on Abiomed’s report, noting good adoption trends for the company’s Impella heart pump in the percutaneous coronary intervention (PCI) market